Glycated hemoglobin as a prognostic risk marker in nondiabetic patients after acute myocardial infarction: what now?

The pandemic of insulin resistance and diabetes mellitus continues to increase and remains a tremendous threat to global health. It is estimated that 11% of US adults have diabetes mellitus and another 35% have prediabetes based on elevated fasting glucose or glycohemoglobin (HbA1c) levels.1 Despite improvements in the management of cardiovascular risk factors, diabetes mellitus continues to confer an 2-fold increased risk for the development of myriad cardiovascular complications, a finding that is independent of comorbid conditions and remains poorly understood.2